Trial reportInternational journal of chronic obstructive pulmonary disease2016
Low cost biological lung volume reduction therapy for advanced emphysema.
Trial report in International journal of chronic obstructive pulmonary disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03010449 (A Single Arm Pilot Study of Lung Volume Reduction in Severe Emphysema Using Bronchoscopic Autologous Blood Instillation in Combination With Intra-bronchial Valves), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single Arm Pilot Study of Lung Volume Reduction in Severe Emphysema Using Bronchoscopic Autologous Blood Instillation in Combination With Intra-bronchial Valves
Who cites it
11 citing papers in PubMed, 4 citations in OpenAlex.
- Low cost biological lung volume reduction therapy for advanced emphysema.International journal of chronic obstructive pulmonary disease · 2016Trial
- Bronchoscopic lung volume reduction by instillation of fibrinogen and thrombin in COPD patients with homogenous emphysema.BMC pulmonary medicine · 2024Article
- Bronchoscopic Management of COPD and Advances in Therapy.Life (Basel, Switzerland) · 2023Review
- Crosslink bio-adhesives for bronchoscopic lung volume reduction: current status and future direction.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Endoscopic Lung Volume Reduction with Autologous Blood: What is the Evidence?Turkish thoracic journal · 2021Review
- Bronchoscopic Lung Volume Reduction: A 2018 Review and Update.Turkish thoracic journal · 2018Review
- Review of lung sealant technologies for lung volume reduction in pulmonary disease.Medical devices (Auckland, N.Z.) · 2018Review
- The bronchoscopic interventions for chronic obstructive pulmonary disease according to different phenotypes.Journal of thoracic disease · 2017Review
- Clinical highlights: messages from Munich.ERJ open research · 2015Article
- Advanced therapies for COPD-What's on the horizon? Progress in lung volume reduction and lung transplantation.Journal of thoracic disease · 2014Review
- Bronchoscopic interventions for emphysema: Current status.Lung India : official organ of Indian Chest SocietyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBronchoscopic lung volume reduction (BLVR), using biological agents, is one of the new alternatives to lung volume reduction surgery.
objectivesTo evaluate efficacy and safety of biological BLVR using low cost agents including autologous blood and fibrin glue.
methodsEnrolled patients were divided into two groups: group A (seven patients) in which autologous blood was used and group B (eight patients) in which fibrin glue was used. The agents were injected through a triple lumen balloon catheter via fiberoptic bronchoscope. Changes in high resolution computerized tomography (HRCT) volumetry, pulmonary function tests, symptoms, and exercise capacity were evaluated at 12 weeks postprocedure as well as for complications.
resultsIn group A, at 12 weeks postprocedure, there was significant improvement in the mean value of HRCT volumetry and residual volume/total lung capacity (% predicted) (P-value: <0.001 and 0.038, respectively). In group B, there was significant improvement in the mean value of HRCT volumetry and (residual volume/total lung capacity % predicted) (P-value: 0.005 and 0.004, respectively). All patients tolerated the procedure with no mortality.
conclusionBLVR using autologous blood and locally prepared fibrin glue is a promising method for therapy of advanced emphysema in term of efficacy, safety as well as cost effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.